Abstract Body

Background

Lenacapavir (LEN), a first-in-class HIV-1 capsid inhibitor, is unique in that it can inhibit HIV-1 infection through multiple mechanisms, affecting both early and late stages of the viral life cycle. The efficacy of LEN can be best understood using a previously described metric, Instantaneous Inhibitory Potential (IIP), which includes the dose response curve slope, or Hill coefficient, as well as the IC50 to define the log reduction of single-round infection for any given drug concentration. Effective antiretroviral therapy (ART) requires a minimum IIP of 5, a level not achieved by most antiretroviral drugs when used as single agents. Here we use IIP to quantify independently the early and late stage effects of LEN and their combined effect.

Methods

A single-round infectivity assay is used to quantify infection of CD4+ T lymphoblasts with GFP-encoding single-round pseudoviruses. Early stage effects were analyzed by infecting lymphoblasts in the presence of LEN. To test late stage effects on virus production, pseudoviruses were generated in the presence of LEN and used to infect non-drug treated lymphoblasts.

Results

Both early and late stage inhibition, dose-response curve slopes were >1, indicating positive cooperativity. An inflection in the late stage curve resulted in a higher slope (m = 3.26) in the clinical concentration range. Thus in contrast to previous studies suggesting a dominant effect of early stage inhibition, the effect of LEN on virus production appears to be more important. The early and late stage effects demonstrate synergy relative to the Loewe models. Together, both mechanisms achieve upwards of 5 logs of inhibition at maximal plasma concentration but are unable to maintain this level of suppression throughout dosing.

Conclusions

Our results suggest that the effects of LEN on the later steps of the HIV-1 life cycle (virus production) are particularly important in the clinical concentration range. Synergy between early and late stage effects results in upwards of 5 logs of inhibition at maximum plasma concentration, but this level of suppression is not maintained throughout clinical use. Combinations of LEN and other antiretroviral drugs may be necessary to achieve IIP values above 5 throughout the dosing interval.